StockNews.AI
ZEAL
StockNews.AI
6 hrs

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

1. Zealand Pharma announces Capital Markets Day on December 11, 2025. 2. Focus on obesity market with differentiated pipeline and partnerships. 3. Upcoming Phase 2 and Phase 3 data to be discussed. 4. Presentation by experts highlights credibility and strategic insight. 5. Zealand positioned strongly in a growing healthcare segment.

5m saved
Insight
Article

FAQ

Why Bullish?

The announcement of a Capital Markets Day indicates forthcoming strategic insights. Historical instances show that such announcements typically lead to positive market reactions, particularly for biotech firms with strong developmental pipelines.

How important is it?

The announcement serves as a precursor for significant data releases, crucial for investor sentiment and valuation. The focus on obesity, a major health issue, indicates potential for significant market interest.

Why Long Term?

The planned events will provide data that could significantly influence investor perception and stock price. Similar past cases, like those of Biogen during their data releases, underscore the long-term impact of new pipeline insights.

Related Companies

NVSAMGNSNYPFE
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of the greatest healthcare challenges of our time, and we are in the very early stages of a rapidly evolving market for weight loss therapies. With a differentiated pipeline targeting obesity and related comorbidities, strong partnerships supporting our leading programs, and a solid financial foundation, we are well positioned to realize our vision of becoming a key player in the future management of obesity.” said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma. “Zealand Pharma is now entering a catalyst-rich chapter from a position of strength. At our Capital Markets Day in December, we look forward to setting the stage for upcoming Phase 2 data with petrelintide and Phase 3 data with survodutide, while also sharing insights into our strategy on driving the next wave of innovation.” External experts and thought leaders in the obesity field who will present alongside Zealand Pharma’s management team include Jonathan Roth, PhD, a metabolic researcher and pioneer in amylin-leptin biology; Dr. Louis Aronne, Professor of Clinical Medicine at Weill Cornell Medicine; and Dr. Carel Le Roux, Professor of Experimental Pathology at University College Dublin. Further details regarding the time, venue, and registration logistics for investors and analysts wishing to participate in person will be provided in the coming weeks. A live webcast will be available at https://www.zealandpharma.com/events/. A replay of the webcast will be archived on the company’s website following the presentation. About Zealand PharmaZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com. ContactsAdam Lange (Investors)Vice President, Investor RelationsZealand PharmaEmail: alange@zealandpharma.com Neshat Anis Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@zealandpharma.com Amber Fennell, Jessica Hodgson, Sean Leous (Media)ICR HealthcareZealandPharma@icrhealthcare.com+44 (0) 7739 658 783

Related News